Biocon Subsidiary Acquires Eywa Pharma Inc.'s US Manufacturing Facility for $7.7 Mn

Biocon Generics Inc., a subsidiary of the biotechnology major Biocon, has acquired Eywa Pharma Inc.'s oral solid dosage manufacturing facility in the United States. 

This strategic move comes at a total consideration of $7.7 Mn and is set to reinforce Biocon's presence in the US pharmaceutical market.

Effective September 1, 2023, Biocon Generics Inc. takes over the reins of Eywa's US plant. Following the acquisition deal, the existing workforce of Eywa Pharma Inc. will be absorbed by Biocon Generics Inc.

Further, the acquisition will help the newly acquired facility to expand production capacity to a staggering 2 billion tablets or capsules annually, as per the company's official statement.

Sharing comments on the acquisition, Biocon's MD and CEO, Siddharth Mittal, said, 'œThe acquisition of this US FDA (US Food and Drug Administration) approved facility, our first in the US, will complement Biocon's existing manufacturing capabilities and strengthen our foothold in the US."

In addition to expanding its manufacturing capabilities, this acquisition allows Biocon to accelerate the production of oral solid dosage forms for new products, allowing the company to meet market demands effectively.

Mittal added, "Our focus will be on integrating the acquired facility expeditiously and expanding our portfolio in the region." 

This approach aligns with Biocon's commitment to diversifying its manufacturing infrastructure to ensure a consistent and reliable supply of pharmaceuticals, he said.

With the acquisition of Eywa Pharma Inc.'s manufacturing facility in the United States, Biocon takes a bold step toward strengthening its presence in the US pharmaceutical market. 

In April 2023, Biocon Biologics' B3 plant in Bengaluru, India, obtained GMP certification from the Health Products Regulatory Authority in Ireland for manufacturing the biosimilar Bevacizumab. This biosimilar is designed to treat multiple cancers and a specific eye disease. 

Additionally, the company is producing and marketing new biosimilars, biologics, and complex small molecule APIs, catering to both the Indian and global markets.